학술논문

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, 1 January 2022, 28(1):106-115)
Subject
Language
English
ISSN
15573265
10780432